Oncocross KRX:382150KOSDAQ
온코크로스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days4
Articles tracked6since Sep 11
In Q3 2026, Oncocross reported an operating loss of ₩2.9bn. Oncocross (온코크로스) appeared in 1 Korean news article and 4 DART filings over the past seven days. Coverage peaked on Nov 12 with 1 article.
Filing signals Insider buying 4 quarters of losses Screener
Oncocross quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | – | – | −₩2.9bn | −₩3.6bn |
| Q2 2026 | – | – | −₩2.7bn | ₩1.0bn |
| Q1 2026 | – | – | −₩2.5bn | −₩2.6bn |
| Q4 2025 derived | – | – | – | −₩2.9bn |
| Q3 2025 | ₩29m | -84.0% | −₩2.4bn | −₩2.0bn |
| Q2 2025 | ₩138m | -20.7% | −₩1.9bn | −₩1.8bn |
| Q1 2025 | ₩63m | +3.4% | −₩2.4bn | −₩2.3bn |
| Q4 2024 derived | ₩655m | +3413.2% | −₩2.4bn | −₩2.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Oncocross top stories 2 weeks, by number of outlets
- 1
Latest Oncocross news Korean headlines
-
MajorOncocrosS-Curigin-Omics AI jointly develop dual-target siRNA platform
1 more on this story · 1 outlets
- Oncoross jointly develops dual-target siRNA with Curisn and Omics AI머니투데이 · Oct 26 16:18